Using hypnosis to help with nasogastric intubation in hematology patients
HYPNONAG : Therapeutic Communication Versus Traditional Method for Naso-gastric Intubation in Haematology: Randomized Controlled Clinical Study
This study tests if using hypnosis can make it easier and more comfortable for patients with blood cancers to have a nasogastric tube placed compared to traditional methods.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rennes University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Rennes, Brittany Region and 1 other locations) |
| Trial ID | NCT05790733 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of hypnosis versus traditional methods for placing a nasogastric tube (NGS) in patients with hematological malignancies undergoing chemotherapy. Patients will be randomized into two groups: one receiving standard care with local anesthesia and the other using self-placement of the NGS with the aid of a hypnotherapist. The goal is to assess whether hypnosis can improve patient comfort, reduce anxiety, and enhance caloric intake during prolonged hospitalization. The study aims to provide insights into the benefits of therapeutic communication in medical procedures.
Who should consider this trial
Good fit: Ideal candidates are adults hospitalized for chemotherapy-induced aplasia lasting more than 8 days who require nasogastric intubation.
Not a fit: Patients who are pregnant, in palliative care, or have certain psychiatric conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to a more comfortable and less anxiety-inducing experience for patients requiring nasogastric intubation.
How similar studies have performed: While the use of hypnosis in medical procedures is gaining interest, this specific approach to nasogastric intubation is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient hospitalized for chemotherapy generating an aplasia lasting more than 8 days (hospitalization for 3 weeks) and for whom the insertion of an NGS is required and not yet attempted since admission to the hospital; * Age ≥ 18 years; * Affiliated to a social security scheme; * Having signed a free, informed and written consent. Exclusion Criteria: * Pregnant or breastfeeding women; * Patient who refuses NGS; * Emergency surgery; * Patients consuming long-term opiates before surgery; * Substance addiction; * Patient at the end of life and/or in palliative care; * Patient unable to answer a questionnaire and/or unable to understand the rating scales; * Deaf and/or dumb patients; * Patients with psychiatric pathologies (schizophrenia, bipolarity); * Persons subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.
Where this trial is running
Rennes, Brittany Region and 1 other locations
- Rennes University Hospital — Rennes, Brittany Region, France (Recruiting)
- Tours University Hospital — Tours, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Magali GRANGER, nurse
- Email: magali.granger@chu-rennes.fr
- Phone: 02 99 28 43 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.